CO2019012118A2 - Anticuerpo anti-pd-l1 y uso del mismo - Google Patents

Anticuerpo anti-pd-l1 y uso del mismo

Info

Publication number
CO2019012118A2
CO2019012118A2 CONC2019/0012118A CO2019012118A CO2019012118A2 CO 2019012118 A2 CO2019012118 A2 CO 2019012118A2 CO 2019012118 A CO2019012118 A CO 2019012118A CO 2019012118 A2 CO2019012118 A2 CO 2019012118A2
Authority
CO
Colombia
Prior art keywords
antibodies
fully human
affinity
disclosed
human anti
Prior art date
Application number
CONC2019/0012118A
Other languages
English (en)
Spanish (es)
Inventor
Yan Lavrovsky
Ting Xu
Sergei Barbashov
Alexey Repik
Mikhail Samsonov
Vasily Ignatiev
Shorena Archuadze
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of CO2019012118A2 publication Critical patent/CO2019012118A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CONC2019/0012118A 2017-04-18 2019-10-29 Anticuerpo anti-pd-l1 y uso del mismo CO2019012118A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
CO2019012118A2 true CO2019012118A2 (es) 2020-04-01

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012118A CO2019012118A2 (es) 2017-04-18 2019-10-29 Anticuerpo anti-pd-l1 y uso del mismo

Country Status (17)

Country Link
US (1) US20210115143A1 (https=)
EP (1) EP3612565A4 (https=)
JP (2) JP2020517239A (https=)
KR (1) KR102323960B1 (https=)
CN (1) CN110856446A (https=)
AU (1) AU2018256392B2 (https=)
BR (1) BR112019021828B1 (https=)
CA (1) CA3059447A1 (https=)
CL (1) CL2019002953A1 (https=)
CO (1) CO2019012118A2 (https=)
EA (1) EA201900443A1 (https=)
MA (1) MA50038A (https=)
MX (1) MX2019012461A (https=)
MY (1) MY199319A (https=)
PH (1) PH12019502302A1 (https=)
SG (1) SG11201909041SA (https=)
WO (1) WO2018195226A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN113677709B (zh) * 2019-04-11 2024-08-23 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
EP3833691B1 (en) * 2019-04-26 2024-09-25 I-Mab Biopharma Co., Ltd. Human pd-l1 antibodies
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CN116178545B (zh) * 2021-09-24 2025-09-12 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2015061668A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2940242C (en) * 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN117088979A (zh) * 2016-10-30 2023-11-21 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体

Also Published As

Publication number Publication date
EP3612565A4 (en) 2021-06-16
EA201900443A1 (ru) 2020-03-06
MA50038A (fr) 2020-07-08
MX2019012461A (es) 2019-12-11
PH12019502302A1 (en) 2020-09-21
JP2020517239A (ja) 2020-06-18
KR20190141169A (ko) 2019-12-23
JP2023025003A (ja) 2023-02-21
SG11201909041SA (en) 2019-11-28
BR112019021828B1 (pt) 2022-09-20
MY199319A (en) 2023-10-24
KR102323960B1 (ko) 2021-11-10
AU2018256392B2 (en) 2024-05-16
BR112019021828A2 (pt) 2020-03-24
WO2018195226A1 (en) 2018-10-25
CA3059447A1 (en) 2018-10-25
CN110856446A (zh) 2020-02-28
AU2018256392A1 (en) 2019-10-17
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CO2019012118A2 (es) Anticuerpo anti-pd-l1 y uso del mismo
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
SA522431756B1 (ar) Tigit أجسام مضادة لـ
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
MX387562B (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
MX2018016404A (es) Anticuerpos de union a cd3.
PH12020500667A1 (en) Multispecific antibodies and use thereof
MX373790B (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
MX2017007537A (es) Anticuerpos anti-pd-1 y sus metodos de uso.
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
EA201791186A1 (ru) Антитела к cd38
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
BR112012028764A2 (pt) anticor-pos antifgfr2
GT201300149A (es) Proteinas de union al tnf-a
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos